サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427696

強直性脊椎炎の世界市場レポート 2024

Ankylosing Spondylitis Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
強直性脊椎炎の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

強直性脊椎炎の市場規模は、今後数年間で大幅な成長が見込まれています。2028年には7.7%の年間複合成長率（CAGR）で78億9,000万米ドルに成長すると予想されます。予測期間の成長は、個別化医療アプローチの採用、新規生物製剤の継続的な開発、早期介入とスクリーニングの重視、ライフスタイルと食事の管理、強直性脊椎炎の治療における遠隔医療と遠隔モニタリングの利用増加に起因すると考えられます。予測期間の主な動向には、バイオシミラーの入手可能性、標的疼痛治療への焦点、患者報告アウトカム（PRO）の重視、コミュニティ支援プログラム、再生医療の探求などが含まれます。

高齢者人口の拡大は、強直性脊椎炎市場の成長軌道を推進することになると予想されています。この人口動態の変化には、高齢者人口の顕著な増加が伴い、60歳以上の人口が大幅に増加しています。強直性脊椎炎治療は、この拡大する層に対応し、疼痛管理を助け、この症状に苦しむ高齢者の可動性を高めます。たとえば、世界保健機関の2022年10月の報告書によると、2030年までに世界中の6人に1人が60歳以上になるとの予測が示されており、高齢者の人口が10億人から14億人へ急増した2020年から大幅に増加しています。その結果、エスカレートする高齢者人口が強直性脊椎炎市場の成長の促進力となっています。

自己免疫疾患の急増により、強直性脊椎炎市場は上昇軌道に乗ると予想されます。自己免疫疾患には、免疫系の異常な反応を特徴とするさまざまな疾患が含まれ、その結果、健康な細胞、組織、臓器が誤って標的化され、損傷を受けます。これらの症状のうち、強直性脊椎炎は、体の免疫システムが誤ってその組織を攻撃し、特に脊椎と骨盤に影響を及ぼす炎症や損傷を引き起こすときに発生します。2023年5月にオックスフォード大学が行った最近の集団ベースの研究で報告されているように、現在自己免疫疾患は約10人に1人が罹患しています。この自己免疫疾患の増加は、強直性脊椎炎市場の将来の拡大に大きく寄与すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の強直性脊椎炎市場の促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界の強直性脊椎炎の市場規模実績と成長、2018年～2023年
  • 世界の強直性脊椎炎の市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の強直性脊椎炎市場、治療タイプ別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 鎮痛剤と非ステロイド性抗炎症薬（NSAIDS）
  • 疾患修飾性抗リウマチ薬（DMARDS）
  • 生物学的療法
  • ステロイド
  • 理学療法
  • 手術
  • 世界の強直性脊椎炎市場、分子別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 生物製剤
  • バイオシミラー
  • 低分子
  • 世界の強直性脊椎炎市場、投与経路別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 非経口
  • 経口
  • その他の経路
  • 世界の強直性脊椎炎市場、用途別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 子ども
  • 大人
  • 世界の強直性脊椎炎市場、エンドユーザー別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 病院
  • クリニック
  • 研究所
  • その他のエンドユーザー

第7章 地域と国の分析

  • 世界の強直性脊椎炎市場、地域別、実績と予測、2018年～2023年、2023年～2028年、2033年
  • 世界の強直性脊椎炎市場、国別、実績と予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 強直性脊椎炎市場の競合情勢
  • 強直性脊椎炎市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Pvt. Ltd.
    • Merck &Co. Inc.
    • AbbVie Inc.
    • Novartis AG

第31章 その他の大手と革新的な企業

  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Boehringer Ingelheim International GmbH
  • Amgen Inc.
  • Cedars-Sinai
  • Viatris Inc.
  • Astellas Pharma Inc.
  • Regeneron Pharmaceuticals Inc.
  • AstraZeneca plc
  • UCB Inc.
  • Cipla Inc.
  • Zydus Lifesciences Limited
  • Celltrion Inc.
  • Hetero Labs Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13540

Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the spine and sacroiliac joints, causing inflammation in the joints and entheses, leading to pain, stiffness, and progressive loss of spinal mobility.

The main treatment modalities for ankylosing spondylitis include painkillers and non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biological therapies, steroids, physical therapies, and surgery. Painkillers and NSAIDs are medications that inhibit the production of specific chemicals causing pain and swelling, aiming to relieve pain and reduce inflammation in AS treatment. Biologics, biosimilars, and small molecules are administered through various routes, including parenteral and oral, catering to both juvenile and adult populations. These treatments are employed by hospitals, clinics, research laboratories, and other end-users.

The ankylosing spondylitis market research report is one of a series of new reports from The Business Research Company that provides ankylosing spondylitis market statistics, including ankylosing spondylitis industry global market size, regional shares, competitors with an ankylosing spondylitis market share, detailed ankylosing spondylitis market segments, market trends and opportunities, and any further data you may need to thrive in the ankylosing spondylitis industry. This ankylosing spondylitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ankylosing spondylitis market size has grown strongly in recent years. It will grow from $5.41 billion in 2023 to $5.86 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to the discovery of HLA-B27, the development of biologic treatments, advancements in pain management approaches, increased patient advocacy and awareness, and the utilization of NSAIDs and disease-modifying drugs in the management of ankylosing spondylitis.

The ankylosing spondylitis market size is expected to see strong growth in the next few years. It will grow to $7.89 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to the adoption of a personalized medicine approach, ongoing development of novel biologics, emphasis on early intervention and screening, management of lifestyle and diet, and the increased utilization of telemedicine and remote monitoring in the treatment of ankylosing spondylitis. Major trends in the forecast period include the availability of biosimilars, the focus on targeted pain therapies, an emphasis on patient-reported outcomes (PROs), community support programs, and exploration of regenerative medicine.

The expansion of the geriatric demographic is set to propel the ankylosing spondylitis market's growth trajectory. This demographic shift involves a notable increase in the elderly population, with a significant rise in individuals aged 60 and above. Ankylosing spondylitis treatments cater to this expanding segment, aiding in pain management and enhancing mobility among older adults affected by this condition. For instance, according to the World Health Organization's October 2022 report, projections indicate that by 2030, one out of every six individuals worldwide will be 60 years or older, marking a substantial increase from 2020, where the population of seniors surged from 1 billion to 1.4 billion. Consequently, the escalating geriatric populace serves as a driving force behind the ankylosing spondylitis market's growth.

The surge in autoimmune diseases is anticipated to drive the upward trajectory of the ankylosing spondylitis market. Autoimmune diseases encompass a diverse array of disorders characterized by the immune system's aberrant response, resulting in the wrongful targeting and harm of healthy cells, tissues, or organs. Ankylosing spondylitis, among these conditions, emerges when the body's immune system erroneously attacks its tissues, causing inflammation and damage, particularly affecting the spine and pelvis. As reported in a recent population-based study by the University of Oxford in May 2023, autoimmune disorders now afflict approximately one in ten individuals. This escalation in autoimmune ailments is expected to significantly contribute to the future expansion of the ankylosing spondylitis market.

Advancements in therapeutic solutions are a prominent trend shaping the landscape of the ankylosing spondylitis market. To fortify their market position, companies invested in this domain are pioneering novel therapeutic options. For instance, Pfizer Inc. secured FDA approval in December 2021 for XELJANZ (tofacitinib) to address active ankylosing spondylitis. This innovative Janus kinase (JAK) inhibitor, effective against five immuno-inflammatory conditions, offers a viable alternative for individuals intolerant or inadequately responsive to tumor necrosis factor (TNF) blockers. Notably, XELJANZ (tofacitinib) boasts the advantage of non-injection or infusion-based administration, providing patients with an alternative delivery method for the medication.

Prominent players in the ankylosing spondylitis arena are fervently developing innovative pharmaceuticals, leveraging enzymatic and cellular assays to cater to various immune-mediated inflammatory conditions. These drugs, validated through meticulous testing on specific enzymes or cell systems, promise precise and targeted interventions for a spectrum of ailments, including moderately to severely active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. AbbVie Inc., in April 2022, secured FDA approval for RINVOQ, a selective JAK inhibitor adeptly evaluated via enzymatic and cellular assays. RINVOQ exhibits heightened potency against JAK-1 compared to JAK-2, JAK-3, and TYK-2, showcasing its therapeutic efficacy across diverse immune-mediated inflammatory diseases, including ankylosing spondylitis (AS).

In April 2021, the Germany-based biopharmaceutical and technology company Merck & Co. Inc. completed the acquisition of Prometheus Biosciences Inc. for $10.8 billion. This strategic acquisition enhances Merck's immunology pipeline by introducing innovations and novel therapeutics, contributing to the broadening, diversification, and strengthening of its portfolio. Prometheus Biosciences Inc., a US-based biotechnology company, is recognized for its contribution to the treatment of ankylosing spondylitis through the development of PRA023.

Major companies operating in the ankylosing spondylitis market report are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., Regeneron Pharmaceuticals Inc., AstraZeneca PLC, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Sandoz International GmbH, Reliance Life Sciences Pvt. Ltd., Affibody Medical AB

North America was the largest region in the ankylosing spondylitis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ankylosing spondylitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ankylosing spondylitis market consists of sales of nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and corticosteroids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ankylosing Spondylitis Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ankylosing spondylitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ankylosing spondylitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ankylosing spondylitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Disease-Modifying Anti-Rheumatic Drugs (DMARDS); Biological Therapies; Steroids; Physical Therapies; Surgery
  • 2) By Molecule: Biologics; Biosimilar; Small Molecules
  • 3) By Route of Administration: Parenteral; Oral; Other Routes
  • 4) By Application: Juveniles; Adults
  • 5) By End User: Hospitals; Clinics; Research Laboratories; Other End Users
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Pvt. Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ankylosing Spondylitis Market Characteristics

3. Ankylosing Spondylitis Market Trends And Strategies

4. Ankylosing Spondylitis Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Ankylosing Spondylitis Market Size and Growth

  • 5.1. Global Ankylosing Spondylitis Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Ankylosing Spondylitis Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Ankylosing Spondylitis Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Ankylosing Spondylitis Market Segmentation

  • 6.1. Global Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Disease-Modifying Anti-Rheumatic Drugs (DMARDS)
  • Biological Therapies
  • Steroids
  • Physical Therapies
  • Surgery
  • 6.2. Global Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Biologics
  • Biosimilars
  • Small Molecules
  • 6.3. Global Ankylosing Spondylitis Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Parenteral
  • Oral
  • Other Routes
  • 6.4. Global Ankylosing Spondylitis Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Juveniles
  • Adults
  • 6.5. Global Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Research Laboratories
  • Other End Users

7. Ankylosing Spondylitis Market Regional And Country Analysis

  • 7.1. Global Ankylosing Spondylitis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Ankylosing Spondylitis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Ankylosing Spondylitis Market

  • 8.1. Asia-Pacific Ankylosing Spondylitis Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Ankylosing Spondylitis Market

  • 9.1. China Ankylosing Spondylitis Market Overview
  • 9.2. China Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Ankylosing Spondylitis Market

  • 10.1. India Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Ankylosing Spondylitis Market

  • 11.1. Japan Ankylosing Spondylitis Market Overview
  • 11.2. Japan Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Ankylosing Spondylitis Market

  • 12.1. Australia Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Ankylosing Spondylitis Market

  • 13.1. Indonesia Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Ankylosing Spondylitis Market

  • 14.1. South Korea Ankylosing Spondylitis Market Overview
  • 14.2. South Korea Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Ankylosing Spondylitis Market

  • 15.1. Western Europe Ankylosing Spondylitis Market Overview
  • 15.2. Western Europe Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Ankylosing Spondylitis Market

  • 16.1. UK Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Ankylosing Spondylitis Market

  • 17.1. Germany Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Ankylosing Spondylitis Market

  • 18.1. France Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Ankylosing Spondylitis Market

  • 19.1. Italy Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Ankylosing Spondylitis Market

  • 20.1. Spain Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Ankylosing Spondylitis Market

  • 21.1. Eastern Europe Ankylosing Spondylitis Market Overview
  • 21.2. Eastern Europe Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Ankylosing Spondylitis Market

  • 22.1. Russia Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Ankylosing Spondylitis Market

  • 23.1. North America Ankylosing Spondylitis Market Overview
  • 23.2. North America Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Ankylosing Spondylitis Market

  • 24.1. USA Ankylosing Spondylitis Market Overview
  • 24.2. USA Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Ankylosing Spondylitis Market

  • 25.1. Canada Ankylosing Spondylitis Market Overview
  • 25.2. Canada Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Ankylosing Spondylitis Market

  • 26.1. South America Ankylosing Spondylitis Market Overview
  • 26.2. South America Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Ankylosing Spondylitis Market

  • 27.1. Brazil Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Ankylosing Spondylitis Market

  • 28.1. Middle East Ankylosing Spondylitis Market Overview
  • 28.2. Middle East Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Ankylosing Spondylitis Market

  • 29.1. Africa Ankylosing Spondylitis Market Overview
  • 29.2. Africa Ankylosing Spondylitis Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Ankylosing Spondylitis Market, Segmentation By Molecule, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Ankylosing Spondylitis Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Ankylosing Spondylitis Market Competitive Landscape And Company Profiles

  • 30.1. Ankylosing Spondylitis Market Competitive Landscape
  • 30.2. Ankylosing Spondylitis Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Pvt. Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Ankylosing Spondylitis Market Other Major And Innovative Companies

  • 31.1. Bristol-Myers Squibb
  • 31.2. Eli Lilly and Company
  • 31.3. Gilead Sciences Inc.
  • 31.4. Boehringer Ingelheim International GmbH
  • 31.5. Amgen Inc.
  • 31.6. Cedars-Sinai
  • 31.7. Viatris Inc.
  • 31.8. Astellas Pharma Inc.
  • 31.9. Regeneron Pharmaceuticals Inc.
  • 31.10. AstraZeneca plc
  • 31.11. UCB Inc.
  • 31.12. Cipla Inc.
  • 31.13. Zydus Lifesciences Limited
  • 31.14. Celltrion Inc.
  • 31.15. Hetero Labs Ltd.

32. Global Ankylosing Spondylitis Market Competitive Benchmarking

33. Global Ankylosing Spondylitis Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Ankylosing Spondylitis Market

35. Ankylosing Spondylitis Market Future Outlook and Potential Analysis

  • 35.1 Ankylosing Spondylitis Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Ankylosing Spondylitis Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Ankylosing Spondylitis Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer